Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) had its price objective decreased by Evercore ISI from $605.00 to $445.00 in a research note published on Thursday morning, The Fly reports. Evercore ISI currently has an outperform rating on the biopharmaceutical company’s stock.
A number of other analysts have also recently weighed in on the stock. J P Morgan Chase & Co restated a hold rating on shares of Regeneron Pharmaceuticals in a report on Tuesday, October 31st. Barclays PLC cut shares of Regeneron Pharmaceuticals from an equal weight rating to an underweight rating and reduced their target price for the stock from $450.00 to $395.00 in a report on Friday, October 20th. Guggenheim restated a buy rating and set a $540.00 target price on shares of Regeneron Pharmaceuticals in a report on Monday, October 23rd. Morgan Stanley restated an equal weight rating and set a $490.00 target price (up from $450.00) on shares of Regeneron Pharmaceuticals in a report on Friday, October 6th. Finally, BMO Capital Markets restated a market perform rating and set a $484.00 target price (up from $421.00) on shares of Regeneron Pharmaceuticals in a report on Friday, July 21st. Two analysts have rated the stock with a sell rating, fifteen have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of Hold and a consensus price target of $475.34.
Regeneron Pharmaceuticals (NASDAQ REGN) traded down $3.10 during midday trading on Thursday, hitting $391.59. 669,073 shares of the company were exchanged, compared to its average volume of 969,574. Regeneron Pharmaceuticals has a fifty-two week low of $340.09 and a fifty-two week high of $543.55. The company has a quick ratio of 3.07, a current ratio of 3.63 and a debt-to-equity ratio of 0.12. The firm has a market capitalization of $41,959.26, a price-to-earnings ratio of 33.90, a PEG ratio of 1.54 and a beta of 1.56.
TRADEMARK VIOLATION NOTICE: This story was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://sportsperspectives.com/2017/11/19/evercore-isi-cuts-regeneron-pharmaceuticals-inc-regn-price-target-to-445-00.html.
In other Regeneron Pharmaceuticals news, major shareholder Sanofi purchased 166,415 shares of the business’s stock in a transaction dated Thursday, August 24th. The shares were acquired at an average price of $480.93 per share, for a total transaction of $80,033,965.95. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, Director Michael S. Brown sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, October 5th. The stock was sold at an average price of $475.00, for a total transaction of $712,500.00. The disclosure for this sale can be found here. Insiders have sold a total of 61,460 shares of company stock worth $29,143,390 in the last 90 days. 10.80% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Alpha Windward LLC raised its holdings in Regeneron Pharmaceuticals by 0.3% in the 2nd quarter. Alpha Windward LLC now owns 384 shares of the biopharmaceutical company’s stock worth $189,000 after acquiring an additional 1 shares during the period. Regentatlantic Capital LLC raised its holdings in Regeneron Pharmaceuticals by 0.9% in the 2nd quarter. Regentatlantic Capital LLC now owns 537 shares of the biopharmaceutical company’s stock worth $264,000 after acquiring an additional 5 shares during the period. Capital Planning Advisors LLC raised its holdings in Regeneron Pharmaceuticals by 2.1% in the 2nd quarter. Capital Planning Advisors LLC now owns 582 shares of the biopharmaceutical company’s stock worth $286,000 after acquiring an additional 12 shares during the period. Sequoia Financial Advisors LLC raised its holdings in Regeneron Pharmaceuticals by 1.7% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 712 shares of the biopharmaceutical company’s stock worth $350,000 after acquiring an additional 12 shares during the period. Finally, Princeton Capital Management Inc. raised its holdings in Regeneron Pharmaceuticals by 0.6% in the 2nd quarter. Princeton Capital Management Inc. now owns 2,511 shares of the biopharmaceutical company’s stock worth $1,233,000 after acquiring an additional 15 shares during the period. Hedge funds and other institutional investors own 67.80% of the company’s stock.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.